An interventional study of Controlled Temperature and Humidity Exposure in Asthma, sponsored by University of Ontario Institute of Technology. Not yet recruiting at 1 site in Canada. Open to participants aged 11 Years to 18 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-07.
Sponsored by University of Ontario Institute of Technology · Not applicable, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 429 studies in Asthma with a site in Canada — 42 open to participants now, 57 under way, 11 of them phase 3. Asthma · Canada.
Among the 429 studies in Asthma with a site in Canada, this one is the 215th largest by planned enrollment of the 367 interventional ones that give a count, is one of 13 that started in 2026, is one of 85 with no phase, reaches primary completion later than 35 of the 56 other live ones, and was the 428th registered.
4,850 studies on the registry are indexed under Asthma; 604 are open to participants now.
Browse Asthma studies →42 of the 429 studies in Asthma with a site in Canada are open now. Recruiting first, the newest first:
GlaxoSmithKline · Sites in Canada, United States, Argentina and 1 more country
Ages 18+
AstraZeneca · Sites in Canada, United States, Argentina and 11 more countries
Ages 6+
University of British Columbia · Sites in Canada
Ages 19–80 · Healthy volunteers
University of Saskatchewan · Sites in Canada
Ages 18+ · Healthy volunteers
University of Alberta · Sites in Canada
Ages 18–55
A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →
Of the 416 Asthma studies recruiting now, 141 (34%) set no upper age limit and 204 (49%) stop at 75 or younger; 146 take children under 18; 105 take healthy volunteers.
This study: 11 Years to 18 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
429 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 21 · Phase 2 105 · Phase 3 106 · Phase 4 59
First in 1998; this study’s year is marked. 13 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 60 is below the median of 79 across 3,346 interventional studies indexed under Asthma.
Median enrollment 110 across the 367 interventional studies, 104 across the 60 observational. Of the 342 that completed or were terminated, 147 (43%) have results posted.
This tab as a report to print or save as PDF → With an account.
228 of 429 have an industry lead sponsor. The 10 most frequent:
University of Ontario Institute of Technology is the lead sponsor of 9 studies on the registry; 2 are open to participants now.
University of Ontario Institute of Technology has 1 study filed under Asthma — fewer than ten, so there is no comparison to draw.
18 of the studies in Asthma with a site in Canada that are under way reach primary completion within a year, 4 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07645248Phase 3GlaxoSmithKlineA Study to Compare Safety of 4 Weeks Exposure to Propellants Hydrofluoroalkane 1,1-difluoroethane (HFA-152a) and HFA-1,1,1,2-tetrafluoroethane (134a) | 2026-12-28 |
| NCT06052267Phase 3Teva Branded Pharmaceutical Products R&D LLCA Study to Test if a Fixed-Dose Combination of Fluticasone Propionate/Albuterol Sulfate is Effective in Preventing Asthma Exacerbations | 2026-12-31 |
| NCT06473779Phase 3AstraZenecaOpen-label Study to Assess Reduction of Background Asthma Medication While Sustaining Asthma Control and Clinical Remission With Tezepelumab in Patients 12-80yrs With Severe Asthma. | 2027-06-25 |
| NCT06785272Phase 3Suzanne SchuhMagnesium Trial in Acute Asthma in Emergency Department | 2027-10 |
| NCT06705764University of AlbertaTezepelumab in the Treatment of Emergency Room Asthma in Adults (TERAA) | 2026-11 |
Add all 18 to your calendar (.ics) → With an account.
Among the 429 studies in Asthma with a site in Canada, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this clinical study is to learn how different temperature and humidity conditions affect breathing, lung function, exercise capacity, symptoms, and other physical responses in children and youth aged 11 to 18 years with asthma, compared with age- and sex-matched children and youth without asthma.
The main questions it aims to answer are:
Researchers will compare children and youth with asthma to age- and sex-matched children and youth without asthma to see if temperature and humidity exposures have different effects on breathing, exercise performance, symptoms, and physiological responses.
Participants will:
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Children and youth aged 11 to 18 years with asthma will be exposed to five controlled temperature and humidity conditions (ideal, cold dry, cold humid, hot dry, and hot humid) in a climatic chamber. Lung function, breathing symptoms, exercise capacity, and physiological responses will be measured before, during, and after each exposure.
Other: Controlled Temperature and Humidity Exposure
Age- and sex-matched children and youth without asthma will undergo the same environmental exposures and assessments as the asthma group to allow comparison of responses between groups.
Other: Controlled Temperature and Humidity Exposure
Exposure to five controlled environmental conditions in a climatic chamber: ideal (18°C, 50-60% RH), cold dry (-15°C, 30-40% RH), cold humid (-15°C, 95-100% RH), hot dry (+35°C, 30-40% RH), and hot humid (+35°C, 95-100% RH). Participants undergo lung function testing, exercise testing, symptom assessments, and physiological monitoring during and after exposures.
Change in Lung Function as Measured by Forced Expiratory Volume in 1 Second (FEV1)
Spirometry will be performed using the In2itive™ (Vitalograph, UK) to assess lung function. FEV1 in mL will be used to evaluate the effects of different temperature and humidity exposures.
Time frame: Measured 1-5 min before entering each temperature/humidity condition, 1-5 min after entering the chamber, and 1-5 min after mCAFT. Day 1 is ~2 weeks after enrollment; Day 2 ~2 weeks later. Conditions are separated by 45 min washout.
Change in Forced Vital Capacity (FVC)
FVC in mL will be measured using the In2itive™ (Vitalograph, UK) to assess lung function.
Time frame: Measured 1-5 min before entering each temperature/humidity condition, 1-5 min after entering the chamber, and 1-5 min after mCAFT. Day 1 is ~2 weeks after enrollment; Day 2 ~2 weeks later. Conditions are separated by 45 min washout.
Change in Peak Expiratory Flow (PEF)
PEF in L/min will be measured using the In2itive™ (Vitalograph, UK) to assess lung function.
Time frame: Measured 1-5 min before entering each temperature/humidity condition, 1-5 min after entering the chamber, and 1-5 min after mCAFT. Day 1 is ~2 weeks after enrollment; Day 2 ~2 weeks later. Conditions are separated by 45 min washout.
Change in FEV1/FVC Ratio
The FEV1/FVC ratio (%) will be calculated from spirometry measurements using the In2itive™ (Vitalograph, UK) to assess airflow limitation.
Time frame: Measured 1-5 min before entering each temperature/humidity condition, 1-5 min after entering the chamber, and 1-5 min after mCAFT. Day 1 is ~2 weeks after enrollment; Day 2 ~2 weeks later. Conditions are separated by 45 min washout.
Airway inflammation
Fractional exhaled nitric oxide (FeNO) will be measured using the NIOX VERO device as a non-invasive biomarker of airway inflammation, measured in parts per billion (ppb).
Time frame: Measured 1-5 min before entering each temperature/humidity condition, 1-5 min after entering the chamber, and 1-5 min after mCAFT. Day 1 is ~2 weeks after enrollment; Day 2 ~2 weeks later. Conditions are separated by 45 min washout.
Heart Rate
Heart rate will be continuously measured using the Zephyr BioHarness and Athena physiological measurement system. Heart rate will be reported in beats per minute (bpm).
Time frame: Continuously monitored beginning prior to chamber entry and throughout each temperature and humidity exposure condition, including pre-, during, and post-mCAFT. Conditions are separated by a 45-minute washout and repeated across 2 study visits.
Respiratory Rate
Respiratory rate will be continuously measured using the Zephyr BioHarness and Athena physiological system. Respiratory rate will be reported in breaths per minute.
Time frame: Continuously monitored beginning immediately prior to chamber entry and throughout each temperature and humidity exposure condition, including the washout periods. Conditions are separated by a 45-minute washout and repeated across 2 study visits.
Heart Rate Variability (HRV)
HRV in milliseconds will be continuously measured using the Zephyr BioHarness and Athena platform to assess responses to temperature and humidity exposures.
Time frame: Continuously monitored beginning immediately prior to chamber entry and throughout each temperature and humidity exposure condition, including the washout periods. Conditions are separated by a 45-minute washout and repeated across 2 study visits.
Skin Temperature
Skin temperature will be continuously measured using the Zephyr BioHarness and Athena physiological measurement platform. Skin temperature will be reported in degree Celsius.
Time frame: Continuously monitored beginning immediately prior to chamber entry and throughout each temperature and humidity exposure condition, including the washout periods. Conditions are separated by a 45-minute washout and repeated across 2 study visits.
Dyspnea
Dyspnea will be assessed using the Modified Borg Scale (no units).
Time frame: Measured 1-5 minutes before entering the chamber, immediately after chamber entry, 1-5 minutes before/after the mCAFT, and after each temperature and humidity exposure. Conditions are separated by a 45-minute washout and repeated across 2 study visits.
Blood Pressure
Blood pressure will be measured before and after the modified Canadian Aerobic Fitness Test using a blood pressure monitor. Blood pressure will be reported in mmHg.
Time frame: Measured at the beginning and end of each study visit and within 1-5 minutes before and after mCAFT during each temperature and humidity exposure. Conditions are separated by a 45-minute washout and repeated across 2 study visits.
Peripheral oxygen saturation (SpO2)
SpO2 will be measured using a fingertip pulse oximeter (Masimo MightySat or Rad-G).
Time frame: Measured during mCAFT within each temperature and humidity exposure condition. Conditions are separated by a 45-minute washout and repeated across 2 study visits.
Rate of Perceived Exertion (RPE)
RPE will be assessed using Borg 6-20 scale. RPE will be reported as a score from 6-20.
Time frame: Assessed 1- 5 minutes before and 1- 5 minutes after mCAFT testing. Conditions are separated by a 45-minute washout and repeated across 2 study visits.
Change in Estimated Peak Oxygen Uptake (VO₂peak) as Measured by the Modified Canadian Aerobic Fitness Test (mCAFT)
The Modified Canadian Aerobic Fitness Test (mCAFT) will be used to measure exercise capacity. It is a progressive submaximal step test used to estimate peak oxygen uptake (VO₂peak). Participants will complete 3-minute stepping stages of increasing intensity, with cadence and step height adjusted according to age and sex. Estimated peak oxygen uptake (VO₂peak) will be calculated and reported in mL/kg/min.
Time frame: Measured during the mCAFT within each temperature and humidity exposure condition. Assessments are repeated across two study visits approximately 2 weeks apart, with a 45-minute washout between conditions.
Change in Maximum Stage Achieved on the Modified Canadian Aerobic Fitness Test (mCAFT)
The Modified Canadian Aerobic Fitness Test (mCAFT) will be used to measure exercise capacity. It is a progressive submaximal step test consisting of 3-minute stepping stages of increasing intensity, with cadence and step height adjusted according to age and sex. The maximum stage successfully completed by each participant will be recorded.
Time frame: Measured during the Modified Canadian Aerobic Fitness Test (mCAFT) within each temperature and humidity exposure condition. Assessments are repeated across two study visits approximately 2 weeks apart, with a 45-minute washout between conditions.
Respiratory Medications Used Prior to Testing
Respiratory medications used prior to each temperature and humidity exposure condition, including medication name, dose, and time of administration.
Time frame: Recorded prior to each temperature and humidity exposure condition (ideal, cold-dry, cold-humid, hot-dry, and hot-humid) across 2 study visits.
Exposure Duration
Duration of completion of each temperature and humidity exposure condition, calculated as time between chamber entry and chamber exit. Measured in minutes.
Time frame: Measured during each exposure condition (ideal, cold-dry, cold-humid, hot-dry, and hot-humid) across 2 study visits.
Actions Taken in the Chamber
Actions taken during/after each temperature and humidity exposure condition, including rescue respiratory medication use, cooling chair use, provision of coverings (e.g., blankets), early exit from the chamber, and other exposure-related will be noted down by study staff.
Time frame: Measured during/after each temperature and humidity exposure condition (ideal, cold-dry, cold-humid, hot-dry, and hot-humid) across 2 study visits.
Participant Age
Participant age will be collected and reported in years.
Time frame: Measured once during screening and baseline assessments on Day 1 (pre-test), prior to any temperature and humidity exposure conditions.
Sex at Birth
Participant reported sex assigned at birth will be collected and reported as categorical options.
Time frame: Measured once during screening and baseline assessments on day 1 (pre-test), prior to any temperature and humidity exposure conditions.
Gender Identity
Participant reported gender identity will be collected and reported as categorical options.
Time frame: Measured once during screening and baseline assessments on day 1 (pre-test), prior to any temperature and humidity exposure conditions.
Years Since Asthma Diagnosis
Time since diagnosed asthma will be collected and reported in years.
Time frame: Measured once during screening and baseline assessments on day 1 (pre-test), prior to any temperature and humidity exposure conditions.
Asthma Triggers
Participant asthma triggers, including allergic and non-allergic triggers, will be collected and reported as categorical options and free text.
Time frame: Measured once during screening and baseline assessments on day 1 (pre-test), prior to any temperature and humidity exposure conditions.
Height
Participant height will be measured and reported in meters (m).
Time frame: Measured once during screening and baseline assessments on day 1 (pre-test), prior to any temperature and humidity exposure conditions.
Weight
Participant weight will be measured and reported in kilograms (kg).
Time frame: Measured once during screening and baseline assessments on day 1 (pre-test), prior to any temperature and humidity exposure conditions.
Respiratory Medication Use
Current respiratory medication use reported as categorical options and free text.
Time frame: Measured once during screening and baseline assessments on day 1 (pre-test), prior to any temperature and humidity exposure conditions.
Body Mass Index (BMI)
BMI will be calculated from height (m) and weight (kg) and reported in kg/m².
Time frame: Calculated once during screening and baseline assessments on day 1 (pre-test), prior to any temperature and humidity exposure conditions.
Co-Morbidities
Participant reported co-morbid medical conditions will be collected and reported as categorical response options and free text.
Time frame: Measured once during screening and baseline assessments on day 1 (pre-test), prior to any temperature and humidity exposure conditions.
Other Medical Diagnoses
Participant reported medical diagnoses other than asthma will be collected and reported as free text.
Time frame: Measured once during screening and baseline assessments on day 1 (pre-test), prior to any temperature and humidity exposure conditions.
Ethnicity
Participant reported ethnicity will be collected and reported as categorical options.
Time frame: Measured once during screening and baseline assessments on day 1 (pre-test), prior to any temperature and humidity exposure conditions.
Social Determinants of Health
Social determinants of health, including factors that may influence health outcomes and healthcare access, will be collected and reported as questionnaire responses.
Time frame: Measured once during screening and baseline assessments on day 1 (pre-test), prior to any temperature and humidity exposure conditions.
Asthma Control Test (ACT)
Asthma control will be assessed using the ACT, a validated questionnaire that evaluates asthma symptoms, activity limitations, and overall control. Scores range from 5 to 25, with higher scores indicating better asthma control. The ACT will be used to assess changes in asthma control status throughout study participation.
Time frame: Measured at screening/baseline prior to the exposure sessions.
Physical Activity Questionnaire for Older Children (PAQ-C)
The PAQ-C is a self-administered questionnaire that assesses a child's general physical activity level during the previous 7 days. Higher scores indicate greater physical activity.
Time frame: Measured at baseline prior to the exposures.
Physical Activity Questionnaire for Adolescents (PAQ-A)
The PAQ-A is a self-administered questionnaire that assesses an adolescent's general physical activity level during the previous 7 days. Higher scores indicate greater physical activity.
Time frame: Measured at baseline prior to exposures.
Mini Pediatrics Asthma Quality of Life Questionnaire (MiniPAQLQ)
The miniPAQLQ is a self-administered questionnaire that assess asthma-related quality of life in children, including symptoms, activity limitations and emotional function. Higher scores indicate better quality of life.
Time frame: Measured at baseline prior to exposures.
International Study of Asthma & Allergies in Childhood (ISAAC) Core Questionnaire for Asthma
The ISAAC Core Questionnaire for Asthma will be used to assess asthma symptoms and history in control participants to confirm the absence of asthma and other respiratory conditions.
Time frame: Measured at baseline prior to exposures.
Start is estimated for Sep 2026; primary completion for Sep 2027, 12 months later.
Of 601 non-industry interventional studies with no phase under Asthma, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 50. This study's planned 12 months is below that.
Counting every sponsor, half of 651 studies reached it within 23 months; a quarter within 10 and three quarters within 47.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University of Ontario Institute of Technology